NK521 in the Treatment of Advanced Solid Tumors

NCT07657416 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Ovarian Cancer
Malignant Ascites

Interventions

BIOLOGICAL: NK521 Cell Injection
BIOLOGICAL: NK521 Cell Injection

Sponsor

Base Therapeutics (Shanghai) Co., Ltd.